WuXi Biologics (Cayman)WXIBF 97 3-Year ROIIC % is 21.80 as of Dec. 2025, which is 114% above its 10-year median of 10.19. GuruFocus rates WXIBF with a GF Score™ of 97/100 and a GF Value™ of $5.14 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 1,322 Biotechnology companies, WuXi Biologics (Cayman) ranks better than 65.58% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
WuXi Biologics (Cayman)'s 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 21.80%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for WuXi Biologics (Cayman)'s 3-Year ROIIC % or its related term are showing as below:
WXIBF's 3-Year ROIIC % is ranked better than 65.58% of 1322
companies
in the Biotechnology industry
Industry Median: -4.82
vs WXIBF: 21.80
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
WuXi Biologics (Cayman) 3-Year ROIIC % Related Terms
WuXi Biologics (Cayman) 3-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WXIBF vs VRTX, REGN, ALNY: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, WuXi Biologics (Cayman)'s 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WuXi Biologics (Cayman) 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, WuXi Biologics (Cayman)'s 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where WuXi Biologics (Cayman)'s 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
WuXi Biologics (Cayman) (WXIBF) has a 3-Year ROIIC % of 21.80 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on WuXi Biologics (Cayman) and its competitors. This is 114% above median its historical median of 10.19. Over the past decade, WuXi Biologics (Cayman)'s 3-Year ROIIC % has ranged from 5.69 to 21.80. According to the industry distribution chart, WuXi Biologics (Cayman) ranks #455 out of 1322 companies in the Biotechnology industry, placing it in the top 34.4%.
Is WuXi Biologics (Cayman)'s 3-Year ROIIC % too high?
WuXi Biologics (Cayman)'s current 3-Year ROIIC % of 21.80 is 114% above median its 10-year median of 10.19. Over the past 10 years, this metric has ranged from a low of 5.69 to a high of 21.80. Based on the distribution chart, WuXi Biologics (Cayman) ranks #455 out of 1322 companies in the Biotechnology industry, which is above the industry midpoint. Overall, WuXi Biologics (Cayman) has a GF Score™ of 97/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does WuXi Biologics (Cayman)'s 3-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, WuXi Biologics (Cayman) ranks #455 out of 1322 companies for 3-Year ROIIC %. This puts WuXi Biologics (Cayman) in the upper half of its industry. Historically, WuXi Biologics (Cayman)'s own 3-Year ROIIC % has ranged from 5.69 to 21.80 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on WuXi Biologics (Cayman) and its competitors. WuXi Biologics (Cayman)'s current 3-Year ROIIC % is 21.80, which is 114% above median its own 10-year median of 10.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WuXi Biologics (Cayman) stock overvalued right now?
Based on GuruFocus' analysis, WuXi Biologics (Cayman) (WXIBF) is currently considered Modestly Undervalued. The stock's GF Value™ is $5.14, compared to a current price of $4.60 — trading 10.5% below its estimated fair value. The current 3-Year ROIIC % is 21.80, which is 114% above median its 10-year median of 10.19. WuXi Biologics (Cayman)'s overall GF Score™ is 97/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For WuXi Biologics (Cayman) (WXIBF), the current 3-Year ROIIC % is 21.80 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is WuXi Biologics (Cayman) (WXIBF) Overvalued in 2026?
Based on GuruFocus' analysis, WuXi Biologics (Cayman) stock appears to be undervalued.
The current stock price of $4.60 is trading 10.5% below its estimated GF Value™ of $5.14.
GuruFocus considers WuXi Biologics (Cayman) to be Modestly Undervalued.
Key valuation signals for WXIBF:
3-Year ROIIC %: 21.80 (114% above median its 10-year median of 10.19)
GF Value™: $5.14 vs. price of $4.60 (10.5% below fair value)
No single metric tells the full story. See the WXIBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
WuXi Biologics is one of the largest biologics contract development and manufacturing organizations in the world. Incorporated in 2014 following the reorganization of WuXi PharmaTech, WuXi engages in full-lifecycle services beginning from drug discovery, clinical trials, and commercial manufacturing. It focuses on developing refining and manufacturing processes to increase scalability and efficiency for pharmaceutical companies looking to outsource and access specialized knowledge. As of 2024, WuXi derives more than 60% of its revenue from US companies and focuses its operations on high-growth, late-stage, and commercial projects in the biologics sector. WuXi competes with Samsung Biologics, Lonza, and Fujifilm for contracts.
97GF Score
Get the complete analysis for WXIBF
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WXIBF has been successfully added to your 
